Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Twilio Inc (TWLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Twilio Inc — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.81 (market cap $8.88B), while Twilio Inc trades at $264.38 (market cap $41.64B). The key difference: Twilio Inc is far larger — about 4.7× Kymera Therapeutics Inc. Common Stock's market cap, and Twilio Inc is more actively traded (1,972,789 versus 1,028,790). Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Twilio Inc for 56 Days on average.
| KYMR | TWLO | |
|---|---|---|
Market Cap | $8.88B | $41.64B |
Volume | 1,028,790 | 1,972,789 |
Sector | Health | Technology |
52-Week High | $127.31 | $301.27 |
52-Week Low | $55.80 | $106.23 |
Typical Hold Time | 0 Days | 56 Days |
Enterprise Value | $8.27B | $40.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Twilio (TWLO) trades at $281.59, down 0.38% on the day, with strong technical momentum showing a bullish moving average signal. The company demonstrates accelerating revenue growth, reaching $5.07 billion in 2025 with net income turning positive at $33.83 million. Recent inclusion in the S&P 500 index and consistent earnings beats highlight operational strength, though valuation metrics remain elevated with a P/E of 37.45.
Twilio presents a growth opportunity with expanding Voice AI capabilities and double-digit revenue growth, supported by 77% analyst buy ratings. Key risks include premium valuation sensitivity and competitive pressures in customer engagement software. The stock trades above the consensus price target of $257.59, suggesting near-term consolidation potential despite positive long-term fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Twilio Inc
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →
